Short Interest in Matinas BioPharma Holdings Inc (MTNB) Increases By 24.5%

Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) was the recipient of a large growth in short interest during the month of October. As of October 31st, there was short interest totalling 2,750,372 shares, a growth of 24.5% from the October 15th total of 2,209,472 shares. Currently, 3.6% of the shares of the stock are short sold. Based on an average daily volume of 5,311,930 shares, the days-to-cover ratio is currently 0.5 days.

Hedge funds and other institutional investors have recently bought and sold shares of the company. K.J. Harrison & Partners Inc acquired a new position in shares of Matinas BioPharma during the 3rd quarter valued at about $150,000. Paloma Partners Management Co increased its position in Matinas BioPharma by 1,724.7% during the 2nd quarter. Paloma Partners Management Co now owns 317,499 shares of the company’s stock worth $138,000 after purchasing an additional 300,099 shares in the last quarter. Finally, Royal Bank of Canada increased its position in Matinas BioPharma by 134.5% during the 1st quarter. Royal Bank of Canada now owns 784,154 shares of the company’s stock worth $599,000 after purchasing an additional 449,761 shares in the last quarter.

Separately, Maxim Group dropped their price objective on shares of Matinas BioPharma from $3.00 to $2.00 and set a “buy” rating for the company in a research note on Monday, August 13th.

NYSEAMERICAN MTNB opened at $1.11 on Friday. Matinas BioPharma has a 12 month low of $0.32 and a 12 month high of $1.60.

Matinas BioPharma (NYSEAMERICAN:MTNB) last posted its quarterly earnings data on Friday, August 10th. The company reported ($0.04) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.04). The company had revenue of $0.09 million for the quarter.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of United States and international copyright legislation. The legal version of this piece of content can be read at

Matinas BioPharma Company Profile

Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable.

Read More: Call Option

Receive News & Ratings for Matinas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma and related companies with's FREE daily email newsletter.

Leave a Reply